While GATA3 has most intensively been studied in the immune system 1 GATA3 is also expressed in other biological environments such as the human endometrium epithelial cells, where levels are regulated in a cyclic manner 2. GATA3 levels are also considered a good prognostic biomarker in breast tumours. Specifically, in the luminal A subtype of breast cancer GATA3 has both a favorable prognostic outcome, and the highest ERα and GATA3 expression of all breast tumours 3. Consistent with this, basal-like tumours have the lowest GATA3 expression and the worst prognosis. GATA3 has also been shown in murine models to be essential to the development and maintenance of mammary luminal cells 45. There is also tentative data showing that different polymorphisms of the GATA3 gene may associate with differential susceptibility to breast cancer 6.

GATA3 levels have previously been correlated with expression of ERα 7 and both were shown to reciprocally regulate one another at the transcriptional level in a cell-culture based system in a cross-regulatory loop 8. Furthermore, in a meta-analysis of ERα 10 genes were proposed as classifier of ERα positive breast tumours, listing GATA3 as one of these 9. A study has also compared microarray experiments between estradiol-induced genes from MCF-7 cells, and transfected GATA3-induced genes from 293T cells to assess common upregulated genes 10.

In an elegant series of experiments utilizing MMTV-PyMT (polyoma middle T antigen) mice it was first shown that GATA3 expression was downregulated with the transition from adenoma to carcinoma in mammary tumours, and the expression was lost in lung metastases. Infection of the MMTV-PyMT carcinomas with GATA3 upregulated markers of differentiation and resulted in a dramatic 27-fold reduction in lung metasases 11. Further crossing of these mice with an inducible cre-WAP (whey acidic protein – specific to luminal mammary epithelial cells) driven knockout of GATA3, resulted in loss of markers of terminal differentiation, detachment from the basal membrane and apoptosis. This is consistent with the requirement of GATA3 in differentiated tumours.

As described in a recent study known pathway partners have been shown to yield a similar 'meta-analysis coexpression signature' i.e. having a significant overlap of coexpressed genes can link proteins to the same pathways 12. Thus performing independent meta-analyses for ERα and GATA3 (putative pathway partners), then comparing the results for overlapping genes would yield a highly significant number of genes if these transcription factors were in the same pathway. We report here not only that these meta-analyses have a high degree of overlap, but that genes identified are consistent with previous reports of the ERα pathway regulation. Additionally we show this correlation with previously identified ERα target genes by combining our meta-analysis data with both RT-PCR and genome-wide location analysis from other studies. These data not only confirm GATA3 as being a key player in the ERα pathway, but also give fresh insights into the pathway itself.

Using the Oncomine™ integrated cancer profiling database GATA3 and ERα were searched for coexpressing genes 13. Coexpression data from 21 multi-array studies was extracted and analysed, separately for ERα and GATA3. While these studies varied in cancer-types, the overwhelming majority extracted for analysis were breast-cancer based [Additional file 1 and 2]. The frequency of coexpressing genes over the 21 studies was determined and the cutoff set to 3 studies or more (3 studies = 14% frequency overlap – [see Additional file 1 and 2]). Next, to ascertain the extent GATA3 may play a role in ERα pathways the frequency coexpression lists were compared for overlap. Interestingly, there was an extensive overlap between both GATA3 and ERα lists at the cutoff of 3 studies (Figure 1A). Increasing the cutoff to 4 or more studies (almost one-fifth of the studies) did not change the relative overlap with respect to total gene numbers, with 43% of the number of ERα coexpressed genes, and 56% of GATA3 coexpressed genes represented in the overlap (Figure 1B). The overlap data with the frequency cutoff of 4 studies is shown in Table 1.

Every technique has its caveats, and the limitation here is that we are assessing the common genes that are consistently coexpressed with ERα and GATA3 over many different human cancer studies. This implies that coexpressed genes are in the same pathways as GATA3 and ERα. However, the meta-analyses can only infer association within the same pathways, and pathway coexpression at the RNA level might not necessarily translate into protein level. Nevertheless, our data are strongly supported by previous knowledge of the ERα pathway.

A recent study identified 51 genes significantly upregulated in ERα positive breast tumours, using a real-time PCR based approach 16. Attesting to the stringency of the meta-analysis approach used here 32 of theses genes were found to overlap with the ERα coexpression list, while an identical number also overlapped with GATA3 (Table 2). This was reflected in a similar study comparing ERα over-expressed transcripts in both oligonucleotide microarray and SAGE platforms 17, where 27 genes common to the ERα pathway are represented here in our common ERα:GATA3 meta-analysis comparison [see Additional file 3]. These data not only acted as wide-ranging external validation for the individual meta-analyses, but also confirmed the extent of the involvement of GATA3 in ERα pathways.

Furthermore, when compared to a list of genome-wide promoters shown to be bound by ERα in MCF-7 cells 18 or on chromosomes 21 and 22 19, 23 were identified in the ERα meta-analysis list, while 27 were identified within the GATA3 list (Table 3). This again supports both the validity of the meta-analysis technique used here, and the role of GATA3 in ERα pathways. It is also possible that the overlap would be even higher if the ERα genomic location analysis were performed on a pool of human ERα-positive breast tumour samples as opposed to a cell-culture model system. While not to detract from the power of a model system such as MCF-7 there are likely to be a great many differences between a homogeneous cell monolayer and a 3-dimensional cancer made up of a heterogeneous cell population.

Of the 10 classifier genes previously identified in a meta-analysis of ERα, the same 4 were identified in both meta-analyses of this study (ESR1, GATA3, FOXA1, SLC39A6) 9. Once again this adds credence to the high-quality data obtained in our current meta-analyses.

Implicating GATA3 in control of some of these gene products is a microarray experiment performed after overexpression of GATA3 in 293T cells 20. After expression of GATA3 elevated levels of TFF1, TFF3, KRT18, FOXA1, SLC9A3R1, TPD52, BCAS1 were observed, all of which we identified here for both GATA3 and ERα meta-analyses. While 293T are not breast cancer cells, it raises the question of how many more of our predicted pathway partners of GATA3 would be identified if the microarray were repeated in cells such as MCF-7 which also retain high ERα expression. In the example of SLC9A3R1 (NHERF1) which is a putative tumour suppressor, it was shown to increase growth of 2 breast cancer cell lines when knocked down by shRNA 21. If GATA3 does help to control expression of NHERF1 this might be one mechanism consistent with its role in the less-aggressive differentiated luminal A breast cancers. Another example is BCAS1 (NABC1) which is overexpressed in breast carcinomas but downregulated in colorectal tumours 2223. Indeed, overexpression of NABC1 did not result in changes in cell-cycle or anchorage-dependent growth properties in NIH3T3 cells, implying it may not be intrinsically oncogenic 24.

As GATA3 is expressed in, and regulates, luminal epithelial cells and has also been shown to regulate the MUC1 gene it is no surprise that MUC1 is also mostly expressed in luminal breast epithelial cells as well as other glandular epithelia 25. MUC1, when abnormally expressed, leads to a loss of both cell-extracellular and cell-cell contacts. It has also been shown that MUC1 levels can be regulated by estrogen and ERα can bind putative binding sites derived from the MUC1 promoter in-vitro 26. Here we reveal that both GATA3 and ERα coexpress with MUC1 acting as further validation of the meta-analysis technique used here. Furthermore, transfected GATA3 can activate a MUC1 promoter reporter in MCF-7 cells, even in the presence of Tamoxifen i.e. independently to ERα activation. This activation could be repeated in the ERα-negative breast cancer cell line SKBR3 (Figure 2). The activation of ERα pathway genes was also observed with pS2 (TFF1) and KRT18 reporters (Figure 2). These data indicate that GATA3 can have its own impact on the ERα pathway and is not just acting indirectly via ERα.

It has also been postulated that, as the deletion of GATA3 in mammary primordia (by K14-Cre) resulted in an inability to form mammary placodes is similar to that of loss of LEF1, Msx1 and Msx2 these may all be intertwined in a transcriptional network 427. It is of interest that in our present study we observe MSX2 coexpression both with GATA3 and ERα, which helps to support this notion.

Using the meta-analysis data presented it is easy to build up transcriptional networks such as this and all of the data presented strongly supports (1) the quality of the meta-analysis results, (2) the concept that GATA3 is firmly entrenched within ERα pathways. Future in-depth analysis of the data presented may lead to novel aspects of ERα or GATA3 regulated pathways, and help to understand the etiology of ERα-positive breast cancers, and management of their outcomes.

While GATA3 has been identified previously in a meta-analysis of ERα only 10 genes were identified in total 9. Here we give an extensive list of coexpressed ERα genes and for the first time a reciprocal meta-analysis for GATA3 has been performed, and the results compared for overlap. This overlap was considerable, confirming the important role of GATA3 in the ERα pathway. The vital question raised is whether GATA3 is crucial to the ERα pathway only by regulation of ERα levels, or through further control of ERα-regulated genes in concert with ERα itself. The GATA3 overexpression microarray experiment in 293T cells, and our reporter gene assays certainly implies the latter 20. Genome-wide location analysis (ChIP-chip) of GATA3 in a well-established ERα system such as MCF-7 cells, as well as specific analysis of the ERα pathway in GATA3 conditional knockout mice will yield vital information regarding the extent that GATA3 is integral to the ERα pathway.

BW conceived and designed the study, performed the meta-analyses, the reporter assays, and wrote the manuscript. VG critically reviewed the manuscript, and approved the final version.